

Running Head: ESWT in Chronic Pelvic Pain Syndrome-Rayegani et al.

Extracorporeal Shockwave Therapy Combined with Drug Therapy in Chronic Pelvic Pain Syndrome – A Randomized Clinical Trial

Seyed Mansoor Rayegani, M.D¹, Mohammadreza Razzaghi MD², Seyed Ahmad Raeissadat MD³, Farzad Allameh MD-MPH^{4*}, Dariush Eliaspour MD¹, Amirreza Abedi MD⁵, Atefeh Javadi MD¹, Amirhossein Rahavian MD⁵

- 1- Physical Medicine and Rehabilitation Research Center, Shohada-e-Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- 2- Laser Application in Medical Sciences Research Center, Shohada-e-Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- 3- Clinical Development Research Center of Shahid Modarres Hospital, Physical Medicine and Rehabilitation Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- 4- Center of Excellence in Training Laser Application in Medicine, Shohada-e-Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- 5- Department of Urology, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Keywords: chronic pelvic pain syndrome; erectile dysfunction; extracorporeal shock wave therapy; pain management; prostatitis

Abstract

Purpose: Chronic prostatitis/ chronic pelvic pain syndrome (CP/CPPS) is a nonspecific pelvic pain in the absence of signs of infection or other obvious local pathology for at least 3 of the last 6 months. The evidence for treatment is limited so the aim of this study is to investigate the effect of extracorporeal shock wave therapy (ESWT) combined with pharmacotherapy in the treatment of CP/CPPS.

Materials and Methods: In this randomized clinical trial, 31 patients with CP/CPPS were investigated in two groups: the intervention group (n=16) was treated with a combination of an alfa-blocker, an anti-inflammatory agent, a muscle relaxant and a short course of antibiotic in combination with 4 sessions of focused ESWT (a protocol of 3000 impulses, 0.25 mJ/mm² and 3 Hz of frequency); the control group (n=15) received the aforementioned pharmacotherapy with 4 sessions of sham-ESWT. Follow-up was performed 4 and 12 weeks following ESWT by using the Visual Analogue Scale (VAS), International index of Erectile function (IIEF) 5, National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI) and International Prostate Symptom Score (IPSS) questionnaires. Post void residual (PVR) urine and maximum flow rate (Q_{max}) were also assessed in both groups.

Results: The patients mean age was 43.7 ±12.6 years. In both groups, the mean scores of NIH-CPSI (total and sub-domains) and VAS showed statistically significant improvements after 4 and 12 weeks compared to the baseline. ($P < .001$) In the intervention group, IPSS (mean difference: 4.25) and Q_{max} (mean difference: 2.22) were also significantly improved. ($P < .001$) There was a significant improvement in NIH-CPSI (mean difference: 1.1) and VAS scores (mean difference: 1.1) in the intervention group as compared to the control group. ($P < .01$) Q_{max}, PVR and IIEF score were not statistically different in the two groups.

Conclusion: ESWT in combination with pharmacotherapy could improve the treatment outcome in patients with CP/CPPS.

INTRODUCTION

Chronic Prostatitis /Chronic Pelvic pain syndrome (CP/CPPS) is the most frequent urological disorder in men younger than 50 and the third most common urological finding in men over 50 years old.⁽¹⁾

According to the national institute of health (NIH), chronic pelvic pain syndrome (CPPS) is a chronic or persistent pain that lasts 3 months in the last 6 months and is perceived in structures related to the pelvis which is associated with symptoms suggestive of lower urinary tract, sexual, bowel or pelvic floor dysfunction and causes negative emotional and cognitive consequences.^(2, 3)

The prevalence of CPPS is between 3–10 % that affects nearly 15% of all urologic outpatient visits.^(4, 5) Despite its high prevalence and its impact on quality of life (QOL), the pathogenesis of the CPPS is hardly understood. Numerous etiologies are proposed including infection, pelvic floor hyperactivity, local chemical alterations, neurologic components (central sensitization), and perfusion disturbances.^(6, 7) It is important to exclude other genital and pelvic disorders present with pelvic pain before the diagnosis of CPPS.⁽⁸⁾

The determination of the severity of the disease, its progression and treatment response can be assessed by means of reliable questionnaires such as International Prostate Symptom (IPSS) Score and National Institutes of Health-chronic prostatitis index (NIH-CPSI).^(2, 9, 10)

Unknown pathogenesis lead to limitations in the treatment of CPPS. The most common therapeutic approaches are α -receptor blockers, like tamsulosin, antibiotics which cover gram negative germs, analgesics such as nonsteroidal anti-inflammatory drugs (NSAIDs) and 5 α reductase inhibitors used as mono- or combination therapy.⁽¹¹⁻¹³⁾

The second-line treatment protocols include physical therapy, trigger-point massage, electromagnetic treatment, acupuncture, prostate massage, and intraprostatic injection of botulinum toxin A.^(14, 15)

There are many challenging issues in the management of patients with CPPS, such as the possibility of treatment failure by monotherapy or pharmacological side effects in long-term use.⁽¹⁶⁾

Although Extracorporeal Shock Wave Therapy (ESWT) has been successful for other indications such as orthopedic pain syndromes,⁽¹⁷⁾ there is limited evidence whether this approach is also effective for patients with CPPS. A number of mechanisms have been suggested including the increasing of local microvascularization, decreasing passive muscle tone, hyperstimulating nociceptors, interrupting the flow of nerve impulses, or influencing the neuroplasticity of the pain memory.^(18, 19) ESWT is an outpatient procedure without significant side effects that can be simply applied.

According to the mentioned challenges in CPPS treatment and the fact that there is no conclusive data about the effectiveness of combining ESWT and drug therapy, we conducted a sham-controlled randomized clinical trial to study the effects of the combination of ESWT and oral pharmacological treatment in patients with CPPS, which, to the best of our knowledge, has not been performed before.⁽²⁰⁾

MATERIALS AND METHODS

We performed this single-blind randomized controlled clinical trial from May 2017 to February 2018.

Inclusion and exclusion criteria

All patients with chronic prostatitis type IIIB/chronic pelvic pain syndrome who referred to the urology clinic of Shohada-e-Tajrish hospital and met our inclusion criteria were enrolled in this study. The study inclusion criteria were as follows: patients older than 18 years of age diagnosed with type IIIB prostatitis (criteria according to NIH classification)⁽³⁾, patients with pain that lasted 3 months in the last 6 months without clear abnormalities upon urological examination and no evidence of bacteria in urinary and seminal fluid culture tests of patients who were not addicted to drugs and narcotics.

The exclusion criteria of this study included being under treatment by another method at the beginning of the study, other diagnoses such as varicocele, hernia or prostate cancer during workup, PSA >4, bleeding diathesis, history of urethral stricture or hematuria or urinary tract infection in the last year.

The diagnosis of patients was made by a single urologist based on a comprehensive history and physical examination including digital rectal examination, PSA measurement, urine analysis and culture, semen analysis and two cup test.

A combination of an alfa blocker (tamsulosin 0.4mg daily), an NSAID (diclofenac sustained released 100mg daily), a muscle relaxant (baclofen 10mg/BD) for 12 weeks and a short term antibiotic (ofloxacin 300mg/BD for 2 weeks) were started for all patients. In this situation no one deprived from the treatment.

For each patient the questionnaires including IIEF5, IPSS and NIH-CPSI were completed and the degree of pain was assessed using VAS to achieve baseline characteristics by a blind person.

We tried to have a consistent environment for participants and trained the participants well for rating the questionnaires to increase the reliability of our assessments. We also calculated the Cronbach's Alpha for each questionnaire.

Uroflowmetry was also done to obtain maximum flow rate (Q_{max}) and post void residual urine (PVR). We used PC based Wireless Uroflowmeter by MMS from Netherland.

Then with random number table the participants were randomly divided into two groups using opaque envelopes to guarantee the allocation concealment. In this protocol all patients were blind about the future procedure.

Procedure

In the Intervention group, patients were treated by ESWT once a week for 4 weeks. Each time 3000 impulses, with 0.25 mJoules/mm² and 3 Hertz of frequency were delivered. After each 500 pulses, the probe position was changed. In this study we used standard focused electromagnetic

DUOLITH SD1 T-TOP by Storz Medical from Switzerland. The treatment was performed in supine position.

In the sham group, the same protocol was applied for patients but the probe was turned off.

Outcome assessment

The primary outcomes were pain reduction and improvement in urinary symptoms which were evaluated using VAS, NIH-CPSI and IPSS questionnaires. The secondary outcomes included sexual performance which was assessed by IIEF5 questionnaire, objective urinary conditions (Qmax and PVR) and treatment complications.

The follow-up assessments were done 4 and 12 weeks following the first ESWT session. The follow-up study included clinical examinations and filling the questionnaires and taking a focused history of patients' complaints by the same blind person who evaluated the participants at the beginning of the study, besides measuring Qmax and PVR by uroflowmetry.

Statistical Analysis

The data were analyzed by SPSS (version 23). The biostatistician was blind about treatment groups. Statistical analyses such as chi-square, paired *t*-test and independent *t*-test were used. *P* value less than 0.05 implied statistical significance.

RESULTS

Thirty-one male patients were randomly assigned to the intervention group (n=16) and control group (n=15). The CONSORT flow diagram is shown in figure 1. The mean age of the patients in the intervention and sham groups were 44.3 ± 13.8 and 43.07 ± 11.7 years, respectively. The demographic data were summarized in table 1. At baseline, the mean scores of IIEF5, VAS, IPSS and NIH-CPSI were not statistically different in the two groups. The mean scores of objective parameters including Qmax (14.825 ± 6.77 versus 15.23 ± 7.06 , $p=.87$) and PVR (14.75 ± 9.83 versus 16.13 ± 11.84 , $p=.72$) were also similar in both groups.

With respect to within-group data analysis, VAS score, total NIH-CPSI and all subdomains were significantly improved in both groups. The difference became statistically significant 4 and 12 weeks after treatment. (Tables 2). IPSS and Qmax were significantly improved in the intervention group ($p < .006$) but insignificantly improved in the sham group 4 and 12 weeks after treatment. In addition, IIEF5 scores and PVR were not improved in either group at any follow-up time points.

Regarding between-group analysis, the scores of NIH-CPSI subdomains including pain, urinary symptoms and QOL became significantly different in the two groups at week 4. Total NIH-CPSI and VAS scores at this follow-up time point were also significantly different in favor of the intervention group. (Tables 3)

After 12 weeks, the difference between the two groups was also noted and the mean NIH-CPSI total scores including pain, urinary symptoms and QOL subdomains were 13.38 ± 4.70 in the intervention group and 21.53 ± 4.53 in the sham group ($P = .0001$). VAS score was different in the two groups and the mean was 2.81 ± 1.16 versus 4.33 ± 1.54 in the intervention and control group, respectively ($P = .004$). But the mean scores of Qmax (14.6 ± 3.80 versus 16.33 ± 5.42 , $P = .40$) and PVR (14.5 ± 4.30 cc versus 13.50 ± 11.63 cc, $P = .80$) were not significantly different. Also the mean of IIEF5 (17.19 ± 2.71 versus 16.27 ± 3.32 , $P = .34$) and IPSS (11.44 ± 3.66 versus 14 ± 4.53 , $P = .93$) were not different in the two populations. (Table 4)

There were only 18% ($n=4$) and 13% ($n=2$) loss to follow-up in intervention and control groups respectively, yet all the questionnaires were filled by interview on phone and only uroflowmetry was not performed.

In this study, four patients in the intervention group experienced minor complications that included transient hematuria and hematospermia which were not statistically and clinically noteworthy.

DISCUSSION

Our study showed that ESWT and drug therapy could improve urinary symptoms, pain and QOL of patients with CPPS.

Numerous studies in other fields of medicine such as cardiology and orthopedics have shown that ESWT is effective and has no significant side-effects. ^(17,21) This issue was confirmed in the present study.

Furthermore, ESWT is effective to alleviate pain and help to heal tissue. This can be explained by local muscle relaxation and ESWT-induced neovascularization. ^(22, 23)

A randomized double-blind study of ESWT in patients with CPPS done by Zimmermann et al.⁽¹⁹⁾ showed that all outcome parameters improved significantly in the treatment group at month 3 (IPSS: 25% decrease; IIEF: 5.3% increase; NIH-CPSI: 17% decrease; VAS: 50% decrease), with no improvement in the sham-treated group. This study is the first to recommend level 1 evidence for ESWT in patients with CPPS. ⁽¹⁹⁾

In the study of 80 CPPS patients, ⁽²⁴⁾ there was a significant improvement in pain, QOL and total NIH-CPSI scores in the ESWT group compared to the sham group.

In our study, an improvement in symptoms was observed in both intervention and sham groups that can be in line with the sham effect and also the medications used in both groups. However, the difference became significant at weeks 4 and 12 after treatment for VAS and NIH-CPSI total and subdomain scores in favor of ESWT. Yet IPSS was not significantly different in each follow-up time.

In most studies ^(23, 25, 26), identical to the present research, focused ESWT was used, with the exception of only one study. ⁽²⁷⁾ In this randomized controlled study a radial shock wave device was used in CPPS patients and the outcomes were compared with the second group in which pharmacological treatment was administrated. A significant improvement of pain and QOL was reported in the first group.

In the present study, Qmax and PVR were not significantly different in the two groups in each follow-up time, while the study conducted by Pajovic et al. ⁽²⁵⁾ showed statistically significant improvement in both PVR and Qmax after receiving a combination of triple drug therapy and

ESWT, which could be due to the longer duration of treatment (12 sessions of ESWT, once-weekly)

Although, in this study, the mean score of IIEF at the baseline was similar to some previous studies, there were no significant changes in our follow-up study, contrary to the findings of above-mentioned studies. ^(19, 28, 29)

The average of follow-up in most studies was 12 weeks after ESWT ^(19, 24, 26, 27) but some studies extended their follow-up ranging from 24 weeks to one year. ^(25, 29, 30) Moayednia et al. ⁽³⁰⁾ showed that at week 24 of follow-up, the mean scores of pain, urinary symptoms, QOL and total NIH-CPSI score were not statistically different from baseline in the ESWT group. While in another study ⁽²⁹⁾ the efficacy of shock wave was proven for one year after treatment. It seems that further studies are needed to determine its long-term efficacy.

Although our data look very promising, some limiting factors in our study need to be considered: the study period of only 3 months is short, therefore, the durability of this approach is unknown.

The lack of side-effects specific to ESWT make it possible to repeat the ESWT cycle at any time. In the future, it might be possible to significantly extend the treatment sessions possibly to achieve a longer-lasting treatment effect.

CONCLUSION

ESWT is an outpatient and easy procedure that, in combination with pharmacotherapy, could improve the treatment outcomes in patients with CP/CPPS.

ACKNOWLEDGEMENTS

We would like to thank the Laser Application in Medical Sciences Research Center personnel for their cooperation and compassion.

Declarations

Ethics approval and consent to participate

The study protocol was performed in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Shahid Beheshti University of Medical Sciences and it is registered on IRCT database with the following code: IRCT2017082635911N1. The informed consent was obtained after all patients were informed of the treatment methods and also about publishing the data without disclosure of their names. It must be mention that there was no deviations from this study protocol in all phases of the project.

Availability of data and materials

All materials described in the manuscript, including relevant raw data, will be freely available to any scientist wishing to use them for non-commercial purposes.

CONFLICT OF INTEREST

It should be mentioned that the authors had no conflict of interest during this mission.

Funding

There was no funding related to this article.

Corresponding author address

Center of Excellence in Training Laser Application in Medicine, Shohada-e-Tajrish Hospital, Tajrish Sq., Tehran, Iran. Email: farzadallame@gmail.com , Cell: +989123885545, Fax: +982122736386

REFERENCES

1. Collins MM, Stafford RS, O'leary MP, Barry MJ. How common is prostatitis? A national survey of physician visits. *J Urol*. 1998;159:1224-8.
2. Fall M, Baranowski AP, Elneil S, Engeler D, Hughes J, Messelink EJ, et al. EAU guidelines on chronic pelvic pain. *Eur Urol*. 2010;57:35-48.
3. Krieger JN, Nyberg Jr L, Nickel JC. NIH consensus definition and classification of prostatitis. *Jama*. 1999;282:236-7.
4. Bartoletti R, Cai T, Mondaini N, Dinelli N, Pinzi N, Pavone C, et al. Prevalence, incidence estimation, risk factors and characterization of chronic prostatitis/chronic pelvic pain syndrome in urological hospital outpatients in Italy: results of a multicenter case-control observational study. *J Urol*. 2007;178:2411-5.
5. Marszalek M, Wehrberger C, Hochreiter W, Temml C, Madersbacher S. Symptoms suggestive of chronic pelvic pain syndrome in an urban population: prevalence and associations with lower urinary tract symptoms and erectile function. *J Urol*. 2007;177:1815-9.
6. Korkmaz S, Karadag MA, Hamamcioglu K, Sofikerim M, Aksu M. Electrophysiological identification of central sensitization in patients with chronic prostatitis. *Urol J*. 2015;12:2280-4.
7. Pontari MA, Ruggieri MR. Mechanisms in prostatitis/chronic pelvic pain syndrome. *J Urol*. 2008;179:S61-S7.
8. Yanev K, Krastanov A, Georgiev M, Tonev A, Timev A, Elenkov A. A Case of Masson's Tumor of the Penis Presenting as Chronic Pelvic Pain Syndrome. *Urol J*. 2018.
9. Litwin MS, McNaughton-Collins M, FOWLER JR FJ, Nickel JC, Calhoun EA, Pontari MA, et al. The National Institutes of Health chronic prostatitis symptom index: development and validation of a new outcome measure. *J Urol*. 1999;162:369-75.
10. Delavierre D, Rigaud J, Sibert L, Labat J. Symptomatic approach to chronic prostatitis/chronic pelvic pain syndrome. *Prog Urol*. 2010;20:940-53.
11. Weidner W, Wagenlehner F, Marconi M, Pilatz A, Pantke K, Diemer T. Acute bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: andrological implications. *Andrologia*. 2008;40:105-12.
12. Propert KJ, Alexander RB, Nickel JC, Kusek JW, Litwin MS, Landis JR, et al. Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome1. *Urology*. 2002;59:870-6.
13. Nickel JC, Downey J, Ardern D, Clark J, Nickel K. Failure of a monotherapy strategy for difficult chronic prostatitis/chronic pelvic pain syndrome. *The Journal of urology*. 2004;172:551-4.
14. Chuang Y-C, Chancellor MB. The application of botulinum toxin in the prostate. *J Urol*. 2006;176:2375-82.
15. Anderson RU, Wise D, Sawyer T, Chan C. Integration of myofascial trigger point release and paradoxical relaxation training treatment of chronic pelvic pain in men. *J Urol*. 2005;174:155-60.
16. Tiselius HG. *Urology: Shock Wave Therapy In Practice: Level 10*; 2013.
17. Schmitz C, Császár NB, Milz S, Schieker M, Maffulli N, Rompe J-D, et al. Efficacy and safety of extracorporeal shock wave therapy for orthopedic conditions: a systematic review on studies listed in the PEDro database. *Br Med Bull*. 2015;116:115.

18. Wess OJ. A neural model for chronic pain and pain relief by extracorporeal shock wave treatment. *Urol Res.* 2008;36:327-34.
19. Zimmermann R, Cumpas A, Miclea F, Janetschek G. Extracorporeal shock wave therapy for the treatment of chronic pelvic pain syndrome in males: a randomised, double-blind, placebo-controlled study. *Eur Urol.* 2009;56:418-24.
20. Marszalek M, Berger I, Madersbacher S. Low-energy extracorporeal shock wave therapy for chronic pelvic pain syndrome: finally, the magic bullet? *European urology.* 2009;56(3):425-6.
21. Wang J, Zhou C, Liu L, Pan X, Guo T. Clinical effect of cardiac shock wave therapy on patients with ischaemic heart disease: a systematic review and meta-analysis. *Eur J Clin Invest.* 2015;45:1270-85.
22. Yan X, Yang G, Cheng L, Chen M, Cheng X, Chai Y, et al. Effect of extracorporeal shock wave therapy on diabetic chronic wound healing and its histological features. *Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi.* 2012;26:961-7.
23. Zimmermann R, Cumpas A, Hoeltl L, Janetschek G, Stenzl A, Miclea F. Extracorporeal shock-wave therapy for treating chronic pelvic pain syndrome: a feasibility study and the first clinical results. *BJU Int.* 2008;102:976-80.
24. Zeng X, Liang C, Ye Z. Extracorporeal shock wave treatment for non-inflammatory chronic pelvic pain syndrome: a prospective, randomized and sham-controlled study. *Chin Med J.* 2012;125:114-8.
25. Pajovic B, Radojevic N, Dimitrovski A, Vukovic M. Comparison of the efficiency of combined extracorporeal shock-wave therapy and triple therapy versus triple therapy itself in Category III B chronic pelvic pain syndrome (CPPS). *Aging Male.* 2016;19:202-7.
26. Vahdatpour B, Alizadeh F, Moayednia A, Emadi M, Khorami MH, Haghdani S. Efficacy of extracorporeal shock wave therapy for the treatment of chronic pelvic pain syndrome: a randomized, controlled trial. *ISRN Urol.* 2013;2013.
27. Nikolaevich KM. Radial Shock Wave Therapy in Chronic Pelvic Pain Syndrome (CPPS). *urology.* 2013;6.
28. Guu S-J, Geng J-H, Chao I-T, Lin H-T, Lee Y-C, Juan Y-S, et al. Efficacy of Low-Intensity Extracorporeal Shock Wave Therapy on Men With Chronic Pelvic Pain Syndrome Refractory to 3-As Therapy. *Am J Mens Health.* 2018;12:441-52.
29. Al Edwan GM, Muheilan MM, Atta ONM. Long term efficacy of extracorporeal shock wave therapy [ESWT] for treatment of refractory chronic abacterial prostatitis. *Ann Med Surg (Lond).* 2017;14:12-7.
30. Moayednia A, Haghdani S, Khosrawi S, Yousefi E, Vahdatpour B. Long-term effect of extracorporeal shock wave therapy on the treatment of chronic pelvic pain syndrome due to non bacterial prostatitis. *J Res Med Sci.* 2014;19:293.

Table 1: Demographic and baseline data in both groups

	Group	N	Mean	Std. Deviation	P Value
Age (years)	case	16	44.38	13.846	0.77
	control	15	43.07	11.708	
Marriage status (number of married)	case	16	8(50%)		1.00
	control	15	7(53.3%)		
Ejaculation per week	case	16	1.50	1.033	0.4
	control	15	1.80	0.941	
Body Mass Index (Kg/m ²)	case	16	29.25	6.382	0.98
	control	15	29.20	6.656	
Duration (months)	case	16	11.37	5.251	0.95
	control	15	11.26	5.885	
IIEF ^a 5	case	16	16.38	6.131	0.66
	control	15	15.47	5.153	
IPSS ^b	case	16	15.69	6.610	0.90
	control	15	15.40	6.208	
NIH ^c pain part	case	16	13.06	6.298	0.44
	control	15	14.67	5.052	
NIH urination part	case	16	4.75	2.817	0.89
	control	15	4.87	1.767	
NIH QOL ^d part	case	16	7.69	2.750	0.44
	control	15	8.33	1.759	
NIH total score	case	16	25.50	8.989	0.42
	control	15	27.87	7.259	

PVR ^e	case	16	14.7500	9.83531	0.72
(ml)	control	15	16.1333	11.84945	
Qmax	case	16	14.825	6.7752	0.87
(ml/s)	control	15	15.233	7.0605	
VAS ^f	case	16	6.44	1.263	0.94
	control	15	6.40	1.805	

^a IIEF: International Index of Erectile Function, ^b IPSS: International Prostate Symptom Score, ^c NIH: National Institute of Health, ^d QOL: Quality of Life, ^e PVR: Post Void Residue, ^f VAS: Visual Analog Scale

Table 2: Mean difference of variables before and after treatment in intervention and control groups after 4 and 12 weeks

Intervention group				
	After 4 weeks		After 12 weeks	
	Mean difference	P Value	Mean difference	P Value
IIEF ^a 5	0.38	0.45	-0.81	0.35
IPSS ^b	1.88	<u>0.006</u>	4.25	<u>0.0001</u>
NIH ^c PAIN	4.25	<u>0.0001</u>	5.06	<u>0.0001</u>
NIHURIN E	2.25	<u>0.0001</u>	2.19	<u>0.001</u>
NIHQOL ^d	3.75	<u>0.0001</u>	4.88	<u>0.0001</u>
NIH Total	10.25	<u>0.0001</u>	12.12	<u>0.0001</u>
Qmax	-2.22	<u>0.004</u>	-1.8	<u>0.04</u>
PVR ^e	2.88	0.056	4.2	0.14
VAS ^f	3.81	<u>0.0001</u>	3.63	<u>0.0001</u>
Control group				
	After 4 weeks		After 12 weeks	
	Mean difference	P Value	Mean difference	P Value
IIEF 5	0.74	0.22	-0.80	0.26
IPSS	0.73	0.6	1.40	0.06
NIH PAIN	2.67	<u>0.001</u>	3.14	<u>0.0001</u>

NIHURIN E	0.87	<u>0.003</u>	0.87	<u>0.0001</u>
NIHQOL	2.4	<u>0.0001</u>	2.33	<u>0.0001</u>
NIH Total	5.94	<u>0.0001</u>	6.34	<u>0.0001</u>
Qmax	-0.59	0.17	0.65	0.20
PVR	1.67	0.10	0.08	0.92
VAS	1.73	<u>0.0001</u>	2.07	<u>0.0001</u>

^a IIEF: International Index of Erectile Function, ^b IPSS: International Prostate Symptom Score, ^c NIH: National Institute of Health, ^d QOL: Quality of Life, ^e PVR: Post Void Residue, ^f VAS: Visual Analog Scale.

Table 3: comparison of outcomes between 2 groups after 4 weeks

	Group	N	Mean	Std. Deviation	P Value
IIEF ^a 5	case	16	16.00	5.177	0.45
	control	15	14.73	3.918	
IPSS ^b	case	16	13.81	4.679	0.64
	control	15	14.67	5.473	
NIH ^c pain part	case	16	8.81	3.351	<u>0.02</u>
	control	15	12.00	3.982	
NIH urination part	case	16	2.50	1.366	<u>0.01</u>
	control	15	4.00	1.690	
NIH QOL ^d part	case	16	3.94	1.340	<u>0.001</u>
	control	15	5.93	1.624	
NIH total score	case	16	15.25	4.282	<u>0.001</u>
	control	15	21.93	5.391	
Qmax	case	16	17.044	4.8814	0.54
	control	15	15.827	6.1762	
PVR ^e	case	16	11.8750	6.66208	0.42
	control	15	14.4667	10.63597	
VAS ^f	case	16	2.63	1.500	<u>0.001</u>
	control	15	4.67	1.447	

^a IIEF: International Index of Erectile Function, ^b IPSS: International Prostate Symptom Score, ^c NIH: National Institute of Health, ^d QOL: Quality of Life, ^e PVR: Post Void Residue, ^f VAS: Visual Analog Scale.

Table 4: comparison of outcomes between 2 groups after 12 weeks

	Group	N	Mean	Std. Deviation	P Value
IIEF ^a 5	case	16	17.19	2.713	0.34
	control	15	16.27	3.327	
IPSS ^b	case	16	11.44	3.669	0.93
	control	15	14.00	4.536	
NIH ^c	case	16	8.00	3.899	<u>0.01</u>
PAIN part	control	15	11.53	3.980	
NIH Urination part	case	16	2.56	1.094	<u>0.003</u>
	control	15	4.00	1.363	
NIH	case	16	2.81	1.047	<u>0.0001</u>
QOL ^d part	control	15	6.00	1.309	
NIH	case	16	13.38	4.703	<u>0.0001</u>
Total score	control	15	21.53	4.533	
Qmax	case	10	14.600	3.8038	0.40
	control	12	16.333	5.4249	
PVR ^e	case	10	14.5000	4.30116	0.80
	control	12	13.5000	11.63459	
VAS ^f	case	16	2.81	1.167	<u>0.004</u>
	control	15	4.33	1.543	

^a IIEF: International Index of Erectile Function, ^b IPSS: International Prostate

Symptom Score, ^c NIH: National Institute of Health, ^d QOL: Quality of Life, ^e PVR: Post

Void Residue, ^f VAS: Visual Analog Scale.




Figure 1- CONSORT 2010 Flow Diagram